Drug Profile
Atrosimab - Baliopharm
Alternative Names: ATM001; AtrosimabLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Baliopharm AG
- Class Anti-inflammatories; Antibodies; Antifibrotics; Hepatoprotectants
- Mechanism of Action Tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Belgium (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Switzerland (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Belgium (Parenteral)